XERMELO

This brand name is authorized in United States. It is also authorized in Austria, Canada, Croatia, Estonia, Finland, France, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Spain, UK.

Active ingredients

The drug XERMELO contains one active pharmaceutical ingredient (API):

1	Telotristat etiprate UNII 8G388563M7 - TELOTRISTAT ETHYL
	Both the prodrug (telotristat ethyl) and its active metabolite (telotristat) are inhibitors of L-tryptophan hydroxylases (TPH1 and TPH2, the rate limiting steps in serotonin biosynthesis). Serotonin plays a critical role in regulating several major physiological processes, including secretion, motility, inflammation, and sensation of the gastrointestinal tract, and is over-secreted in patients with carcinoid syndrome. Through inhibition of peripheral TPH1, telotristat reduces the production of serotonin, thus alleviating symptoms associated with carcinoid syndrome.
	Read more about Telotristat

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
XERMELO Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A16AX15		A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AX Various alimentary tract and metabolism products
Discover more medicines within A16AX15

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02481553
EE	Ravimiamet	1753859, 1753860
ES	Centro de información online de medicamentos de la AEMPS	1171224001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	403615
FR	Base de données publique des médicaments	60705470
GB	Medicines & Healthcare Products Regulatory Agency	348419
IL	מִשְׂרַד הַבְּרִיאוּת	8459
IT	Agenzia del Farmaco	045682010, 045682022
LT	Valstybinė vaistų kontrolės tarnyba	1083945, 1083946
NL	Z-Index G-Standaard, PRK	148075
PL	Rejestru Produktów Leczniczych	100397218
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69129001, W69129002
US	FDA, National Drug Code	70183-125, 70720-125